Transapical Mitral Valve-in-Valve Replacement in Patient with Previous Complex Sternal Reconstruction

2016 ◽  
Vol 11 (3) ◽  
pp. 222-224
Author(s):  
Conor F. Hynes ◽  
Omid Fatemi ◽  
Aditya C. Sharma ◽  
Christian D. Nagy ◽  
Gregory D. Trachiotis
Keyword(s):  
Mitral Valve ◽  
Chest Wall ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Chest Wall Reconstruction ◽  
Complex Case ◽  
Viable Solution ◽  
Sternal Reconstruction ◽  
Valve In Valve ◽  
Mitral Bioprosthesis

We present a complex case of a transapical redo mitral valve-in-valve replacement. Repeat mitral valve replacement was indicated for severe symptomatic bioprosthetic stenosis. In addition to the patient's numerous comorbidities that included diabetes, hepatic cirrhosis, ischemic cardiomyopathy, and atrial flutter, he had undergone a previous open mitral valve replacement that was complicated by sternal dehiscence requiring extensive chest wall reconstruction. Transapical approach was performed through left minithoracotomy incision with balloon-expandable valve. Transapical valve-in-valve replacement of a stenotic mitral bioprosthesis is a viable solution in a patient with previous complex chest wall reconstruction and multiple comorbidities.

scholarly journals Redo Aortic and Mitral Valve Replacement using St. Jude Medical Mechanical Prosthesis in a Patient with Degenerated Mitral Bioprosthesis and Severe Aortic Regurgitation: A Video Presentation

2021 ◽  
Vol 5 (02) ◽  
pp. 151-153
Author(s):  
Ujjwal K. Chowdhury ◽  
Lakshmi Kumari Sankhyan ◽  
Sukhjeet Singh ◽  
Niwin George ◽  
Sandeep Sharan ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Young Patients ◽  
Heart Association ◽  
Mechanical Prosthesis ◽  
Jude Medical ◽  
Severe Aortic Regurgitation ◽  
Valve In Valve ◽  
Mitral Bioprosthesis

AbstractThe American College of Cardiology/American Heart Association practice guidelines suggest bioprosthetic aortic and mitral valve replacement is a reasonable option for patients older than 65 years and for selected patients younger than 65 years according to patients’ preference. However, routine use of bioprosthetic valves in younger patients remains controversial. Patients prevalence to avoid anticoagulation, decreasing operative risks for valve reoperations, and the availability of catheter valve-in-valve techniques have created a need to reexamine bioprosthetic valve durability, particularly in young patients undergoing valve replacements

scholarly journals Acute and Short-Term Outcomes of Percutaneous Transcatheter Mitral Valve Replacement in Children

2021 ◽  
Author(s):  
Nicola Maschietto ◽  
Ashwin Prakash ◽  
Pedro del Nido ◽  
Diego Porras
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Pediatric Patients ◽  
Surgical Techniques ◽  
Postoperative Mortality ◽  
Surgical Risk ◽  
Transcatheter Mitral Valve Replacement ◽  
High Surgical Risk ◽  
Valve In Valve

Background: Despite the improvement of surgical techniques for mitral valve (MV) repair in children, mitral valve replacement (MVR) is sometimes still necessary. MVR and redo-MVR continue to be burdened by early postoperative mortality and long-term morbidity with only about 75% of these patients being alive or transplant-free 10 years after the initial MVR. Although transcatheter MVR (TMVR) is a well-established intervention in high surgical risk adults, only a few pediatric valve-in-valve case reports have been published. The purpose of this study was to describe our initial experience with the off-label use of the Sapien S3 valve for TMVR in a highly selected pediatric patient population. Methods: We conducted a retrospective analysis of pediatric patients who underwent TMVR at Boston Children’s Hospital between October 2018 and July 2020. Results: Eight consecutive high surgical risk pediatric patients (median age, 9 years; range, 8–15) underwent TMVR (7 as valve-in-valve, 1 in a native MV). Each patient previously underwent multiple MV surgeries or MVR (median 4, range 2–5) and was highly symptomatic (Ross functional class 3 or 4). The indication for TMVR was mitral stenosis in 4 patients, regurgitation in 1, and mixed disease in 3. TMVR was successful in each patient, effectively reduced the left atrium and pulmonary hypertension ( P =0.012 and 0.043 respectively), and was carried out without significant complications. Conclusions: TMVR is an attractive alternative to MVR in high surgical risk patients. In this small series, TMVR was acutely effective and safe, with very encouraging early results.

Transapical Mitral Valve-in-Valve Replacement in Patient with Previous Complex Sternal Reconstruction

2016 ◽  
Vol 11 (3) ◽  
pp. 222-224
Author(s):  
Conor F. Hynes ◽  
Omid Fatemi ◽  
Aditya C. Sharma ◽  
Christian D. Nagy ◽  
Gregory D. Trachiotis
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Sternal Reconstruction ◽  
Valve In Valve

scholarly journals Transcatheter Mitral Valve Replacement: Evolution and Future Development

2021 ◽  
Author(s):  
Lina Ya’qoub ◽  
Marvin Eng
Keyword(s):  
Computed Tomography ◽  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Future Research ◽  
Early Outcome ◽  
Transcatheter Mitral Valve Replacement ◽  
Valve In Valve ◽  
Procedural Planning ◽  
Annular Calcification

We will review transcatheter mitral valve replacement (TMVR) and discuss this evolving cutting edge procedure in terms of types (valve in valve, valve in ring and valve in mitral annular calcification MAC), clinical indications, pre-procedural planning and value of pre-procedural imaging including computed tomography role, technical challenges encountered in these procedures, potential complications for each type of TMVR, and potential strategies to mitigate and avoid such complications, We will review the currently available devices dedicated for mitral valve replacement, with a summary of their preliminary data and early outcome results. We will also discuss knowledge gaps and ideas for future research.

Sign in / Sign up

Export Citation Format

Share Document